These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948 [TBL] [Abstract][Full Text] [Related]
3. Natural challenge of subjects vaccinated with WRL 105 strain live influenza vaccine in a residential community. Morris CA; Freestone DS; Stealey VM Dev Biol Stand; 1976; 33():197-201. PubMed ID: 782969 [TBL] [Abstract][Full Text] [Related]
4. Small-scale field trial with neuraminidase vaccine. Vonka V; Závadová H; Brůj J; Skocil V; Janout V; Uvizl M; Kotíková J Dev Biol Stand; 1977 Jun 1-3; 39():337-9. PubMed ID: 342313 [TBL] [Abstract][Full Text] [Related]
5. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981 [TBL] [Abstract][Full Text] [Related]
6. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Muhamed G; Greenbaum E; Zakay-Rones Z Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048 [TBL] [Abstract][Full Text] [Related]
7. Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen. Kim HW; Arrobio JO; Brandt CD; Parrott RH; Murphy BR; Richman DD; Chanock RM Pediatr Res; 1976 Apr; 10(4):238-42. PubMed ID: 1272630 [TBL] [Abstract][Full Text] [Related]
8. Antibody responses to inactivated influenza vaccines and partial protective effect of anti-neuraminidase antibody against epidemics of A(H3N2) and A(H1N1) influenza. Maeda A; Oishi I; Minekawa Y; Kunita N; Funahashi S; Yagura H Biken J; 1979 Sep; 22(3):91-8. PubMed ID: 533537 [No Abstract] [Full Text] [Related]
9. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765 [TBL] [Abstract][Full Text] [Related]
10. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
11. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. de Jong JC; Beyer WE; Palache AM; Rimmelzwaan GF; Osterhaus AD J Med Virol; 2000 May; 61(1):94-9. PubMed ID: 10745239 [TBL] [Abstract][Full Text] [Related]
12. Use of an inhibitor-resistant live attenuated influenza vaccine in normal and asthmatic adults. Warshauer DM; Minor TE; Inhorn SL; Reed CE; Dick EC Dev Biol Stand; 1976; 33():184-90. PubMed ID: 782967 [TBL] [Abstract][Full Text] [Related]
13. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. Hurwitz ES; Haber M; Chang A; Shope T; Teo ST; Giesick JS; Ginsberg MM; Cox NJ J Infect Dis; 2000 Oct; 182(4):1218-21. PubMed ID: 10979921 [TBL] [Abstract][Full Text] [Related]
14. Live attenuated influenza virus vaccine trial in children. Hall CB; Douglas G; Fralonardo SA Pediatrics; 1975 Dec; 56(6):991-8. PubMed ID: 1196767 [TBL] [Abstract][Full Text] [Related]
15. Vaccination of an adolescent group with A (H3N2) + A(HSW1N1) bivaccine before an A (H1N1) influenza epidemic. Stumpa A; Cihla F; Tůmová B; Husek V; Slezácek J Acta Virol; 1979 Sep; 23(5):443-5. PubMed ID: 42307 [TBL] [Abstract][Full Text] [Related]
16. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza I. Hemagglutinationinhibiting antibodies (author's transl)]. Kuwert EK; Werner J; Scheiermann N; Pledt T Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):155-74. PubMed ID: 506543 [TBL] [Abstract][Full Text] [Related]
17. Clinical trials with a new influenza subunit vaccine in adults and children. Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311 [TBL] [Abstract][Full Text] [Related]
18. [Antibody response to hemagglutinin and neuraminidase induced by an influenza subunit vaccine (author's transl)]. Kuwert E; Werner J; Franke G; Paulus W Zentralbl Bakteriol Orig A; 1979 Jun; 244(1):1-16. PubMed ID: 92113 [TBL] [Abstract][Full Text] [Related]
19. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Brett IC; Johansson BE Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702 [TBL] [Abstract][Full Text] [Related]
20. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine]. Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]